Absci

Eli Lilly invested $40 million in Absci, an AI-driven drug company developing ABS-201, an injectable antibody targeting androgenetic alopecia and endometriosis. The investment coincided with Absci releasing positive Phase 1 safety data, and both companies aim to leverage direct-to-consumer strategies and AI-designed drugs to disrupt the injectable market.

Eli Lilly is investing $40 million in Absci, an AI startup developing treatments for hair loss and endometriosis. Absci raised $100 million in total funding led by Eli Lilly, with the startup publicly traded on Nasdaq.